Drug Search Results
More Filters [+]

Ilepatril

Alternative Names: ilepatril, ave-7688, ave7688, ave 7688
Latest Update: 2016-05-18
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: ACE Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ilepatril

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Hypertension

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2005-003521-13

P3

Completed

Unknown

2008-03-20

RAVEL-1

P3

Completed

Hypertension

2008-03-01

2006-7041-83/hah

N/A

Not yet recruiting

Spinal Cord Injuries

None

Recent News Events

Date

Type

Title